Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck

Deteriorated to respirator and recovered 0 High CRP serum levels at hospitalization 10 CRP reduction of 50% and more within 48-72 hours 5 (50%) 2 (10%) Dr. Dorit Arad, Chief Scientific Officer of NLC Pharma commented, “Our biggest hurdle in being able to finalize a full development program for Tollovir in the outpatient setting has been trying to decipher what regulators are likely to accept as an approvable endpoint with regards to safety and efficacy.

Read the source article at tmcnet.com
2021-10-04 15:30:00